- Home
- CINT vs PHVS Comparison
CINT vs PHVS Comparison
Compare CINT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINT
- PHVS
- Stock Information
- Founded
- CINT 1995
- PHVS 2015
- Country
- CINT Brazil
- PHVS Netherlands
- Employees
- CINT N/A
- PHVS N/A
- Industry
- CINT EDP Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- CINT Technology
- PHVS Health Care
- Exchange
- CINT Nasdaq
- PHVS Nasdaq
- Market Cap
- CINT 906.5M
- PHVS 1.0B
- IPO Year
- CINT 2021
- PHVS 2021
- Fundamental
- Price
- CINT $5.90
- PHVS $18.61
- Analyst Decision
- CINT Buy
- PHVS Strong Buy
- Analyst Count
- CINT 7
- PHVS 5
- Target Price
- CINT $7.40
- PHVS $40.60
- AVG Volume (30 Days)
- CINT 65.4K
- PHVS 105.9K
- Earning Date
- CINT 11-14-2024
- PHVS 11-13-2024
- Dividend Yield
- CINT N/A
- PHVS N/A
- EPS Growth
- CINT 15.05
- PHVS N/A
- EPS
- CINT 0.16
- PHVS N/A
- Revenue
- CINT $410,247,558.00
- PHVS N/A
- Revenue This Year
- CINT $6.56
- PHVS N/A
- Revenue Next Year
- CINT $15.42
- PHVS N/A
- P/E Ratio
- CINT $36.73
- PHVS N/A
- Revenue Growth
- CINT N/A
- PHVS N/A
- 52 Week Low
- CINT $3.34
- PHVS $15.37
- 52 Week High
- CINT $8.04
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- CINT 32.33
- PHVS 40.29
- Support Level
- CINT $6.21
- PHVS $17.93
- Resistance Level
- CINT $7.20
- PHVS $20.17
- Average True Range (ATR)
- CINT 0.26
- PHVS 1.53
- MACD
- CINT -0.08
- PHVS -0.15
- Stochastic Oscillator
- CINT 10.34
- PHVS 14.38
About CINT CI&T Inc
CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About PHVS Pharvaris N.V.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .